Fabry Disease

Fabry disease is an inherited lysosomal storage disorder caused by reduced or absent activity of the enzyme alpha-galactosidase A. Without enough of this enzyme, globotriaosylceramide and related fatty substances build up inside cells. Fabry disease can affect people of all sexes and may involve the skin, nerves, kidneys, heart and blood vessels. The condition is also called Fabry syndrome or Fabry’s disease.

Fabry disease results from a disease-causing change, or variant, in the GLA gene. This variant reduces alpha-galactosidase A activity, allowing certain fatty substances to accumulate inside lysosomes, the recycling compartments within cells. The condition follows an X-linked inheritance pattern, but symptoms and severity can vary according to biological sex and the specific GLA variant.

How Fabry Disease Runs in Families

An affected man passes his GLA variant to all of his daughters and none of his sons because daughters receive his X chromosome and sons receive his Y chromosome. An affected woman may pass the variant to either sons or daughters. A family history may be absent because Fabry disease was undiagnosed, symptoms were mild, or a new diagnosis has revealed previously unrecognized cases; lifestyle choices do not cause it.

Regular kidney, heart, neurologic and hearing assessments can identify organ involvement before complications become advanced. Ongoing monitoring helps clinicians adjust Fabry disease therapy and supportive care when needed.

Doctors may consider Fabry disease when a person has characteristic symptoms, unexplained kidney or heart findings, or a family history of the condition. Testing is often coordinated by a metabolic specialist, geneticist or another clinician familiar with inherited lysosomal storage disorders.

Depending on symptoms and family history, assessment may include urine and blood tests, electrocardiography, echocardiography or cardiac MRI, brain imaging, hearing tests and eye examinations. Alpha-galactosidase A activity can be normal or near-normal in some females, so genetic testing is important when Fabry disease is suspected. Testing relatives can identify other family members who may benefit from monitoring or treatment.

Fabry treatment is individualized according to symptoms, organ involvement, age, pregnancy considerations, genetic findings and access to specialist care. Current therapies can manage the condition and help protect organs, but they do not generally provide a complete cure.

Disease-Specific Therapy

Intravenous enzyme replacement therapy replaces the missing alpha-galactosidase A enzyme and is given during scheduled infusion visits. An oral medicine called migalastat may help eligible people whose GLA variant responds to pharmacologic chaperone treatment. Clinicians choose between suitable approaches based on genetic testing, organ involvement, medical factors and treatment suitability.

Treatment may involve regular infusions or oral dosing, depending on the plan. Clinicians monitor for treatment reactions, adherence, symptoms and kidney, heart and neurologic outcomes through periodic reviews. Therapy may slow or manage disease effects, but it cannot be expected to reverse established organ damage in every person.

Supportive Organ and Symptom Care

Supportive care is an important part of managing Fabry disease. It focuses on protecting affected organs, controlling symptoms, and improving quality of life.

Kidney Care

Kidney function should be monitored regularly with blood and urine tests. Medicines such as ACE inhibitors or ARBs may be used to reduce protein loss in the urine and protect kidney function. In advanced kidney disease, dialysis or kidney transplantation may be necessary.

Heart Care

Regular cardiac evaluation is important because Fabry disease can affect the heart. Treatment may include medicines for arrhythmias, heart failure, or other cardiovascular problems. Pacemakers or other cardiac devices may be considered in selected patients.

Pain Management

Pain, particularly burning pain in the hands and feet, is common. Pain-relieving medicines and treatments for nerve pain may help control symptoms. Avoiding triggers such as extreme temperatures can also reduce pain episodes.

Gastrointestinal and Other Symptoms

Gastrointestinal symptoms such as abdominal pain, diarrhea, and constipation can be managed with dietary changes and appropriate medications. Fatigue, hearing problems, and other symptoms should also be evaluated and treated when necessary.

Fabry disease is a lifelong condition with a highly variable course. Some people have mild or late-onset disease, while others develop progressive kidney, heart or neurologic complications. The outlook depends on the specific genetic variant, age at diagnosis, organ involvement and response to ongoing care.

Why Early Care Matters

Early diagnosis and ongoing Fabry treatment can help reduce symptoms, detect organ changes and protect remaining kidney and heart function. Established organ damage may not be reversible, so treatment and monitoring are most useful when started before complications become advanced.

Lifelong follow-up may include periodic kidney, heart, neurologic, hearing and symptom assessments. A specialist team can adjust Fabry disease therapy and supportive care as needs change, but an individual’s life expectancy and outcome cannot be predicted from the diagnosis alone.

Make a medical appointment for unexplained burning pain in the hands or feet, reduced sweating, angiokeratomas, unexplained kidney or heart findings, or a known family history of Fabry disease. Ask about genetic counseling and Fabry disease testing if a close relative has been diagnosed. Females with possible symptoms should also seek assessment because symptoms can vary widely.